ИСТИНА |
Войти в систему Регистрация |
|
ИСТИНА ИНХС РАН |
||
SGLT2 inhibitor Empagliflozin improved systolic function in the early phase post MI independently from glucose regulation. The cardioprotective mechanisms of SGLT2 inhibitors may involve cardiac NHE1 exchanger inhibition.